Ipratropium inhalation is used to prevent bronchospasm, or narrowing airways in the lungs, in people with bronchitis, emphysema, or COPD (chronic obstructive pulmonary disease). This medication will not treat bronchospasm while it is happening but more of preventing attacks of bronchospasm. To best control your condition, use ipratropium inhalation regularly, and continue using all your other prescribed medicines.
Before using this medication, tell your doctor if you have:
• narrow-angle glaucoma; or
• an enlarged prostate or a bladder obstruction.
If you have any of these conditions, you may not be able to use ipratropium inhalation or you may need a dosage adjustment or special tests during treatment.
Ipratropium inhalation should not be used by a child younger than 12 years of age. It is not expected to be harmful to an unborn baby (FDA pregnancy category B) and not known if this medicine passes into breast milk or if it could harm a nursing baby. Do not use ipratropium inhalation without telling your doctor if you are breast-feeding a baby; pregnant or planning to get pregnant.
Call your doctor right away if you feel that this medicine is not working as well as usual, if it makes your condition worse or if you need to use more of any of your medications in a 24-hour period. To be sure this medication is helping your condition, your lung function will need to be tested on a regular basis.
Although ipratropium inhalation is not expected to cause overdose symptoms, seek emergency medical attention if you think you have used too much of this medicine.
Avoid getting this medication in your eyes. If this happens, rinse with water.
Stop using ipratropium inhalation and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat and a fast, pounding heartbeat.
Other less serious side effects are more likely to occur, such as:
• headache, dizziness;
• dry mouth, cough, hoarseness;
• nausea, upset stomach; or
• blurred vision.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
• atropine (Donnatal, and others),
• clidinium (Quarzan),
• dicyclomine (Bentyl),
• glycopyrrolate (Robinul),
• hyoscyamine (Anaspaz, Cystospaz, Levsin, and others)
• mepenzolate (Cantil),
• methantheline (Provocholine),
• methscopolamine (Pamine), and
• propantheline (Pro-Banthine), or
• scopolamine (Transderm-Scop).
If you are using any of these drugs, you may not be able to use ipratropium inhalation, or
you may need dosage adjustments or special tests during treatment.
There may be other drugs not listed that can affect ipratropium inhalation. Tell your doctor about all the prescription and over-the-counter medications such as vitamins, minerals and herbal products that you use.
The active ingredient in Atrovent (ipratropium bromide) is ipratropium bromide monohydrate. It is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo(3.2.1)-octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)- 8-methyl-8-(1-methylethyl)-, bromide, monohydrate(endo, syn)-, (±)-; a synthetic quaternary ammonium compound, chemically related to atropine. ATROVENT Inhalation Aerosol contains a microcrystalline suspension of ipratropium bromide in a pressurized metered-dose aerosol unit for oral inhalation administration. The net weight is at least 14.7 grams; it yields 200 inhalations. Each actuation meters 21 mcg of ipratropium bromide from the valve and delivers 18 mcg of ipratropium bromide from the mouthpiece. The excipients are dichlorodifluoromethane, dichlorotetrafluoroethane, and trichloromonofluoromethane as propellants and soya lecithin.
Ipratropium inhalation has the following structural formula: